Cargando…
Stratification of risk groups according to survival after recurrence in endometrial cancer patients
To identify prognostic factors for overall survival after recurrence (OSr) in endometrioid endometrial cancer (EC) patients and categorize patient subgroups that predict outcomes using these variables. Consecutive patients with recurrent endometrioid EC seen in our institution from 1989 to 2013 were...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457863/ https://www.ncbi.nlm.nih.gov/pubmed/28538383 http://dx.doi.org/10.1097/MD.0000000000006920 |
_version_ | 1783241626990149632 |
---|---|
author | Shim, Seung-Hyuk Kim, Dae-Yeon Kim, Hyun Jung Lee, Shin-Wha Park, Jeong-Yeol Suh, Dae-Shik Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Nam, Joo-Hyun |
author_facet | Shim, Seung-Hyuk Kim, Dae-Yeon Kim, Hyun Jung Lee, Shin-Wha Park, Jeong-Yeol Suh, Dae-Shik Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Nam, Joo-Hyun |
author_sort | Shim, Seung-Hyuk |
collection | PubMed |
description | To identify prognostic factors for overall survival after recurrence (OSr) in endometrioid endometrial cancer (EC) patients and categorize patient subgroups that predict outcomes using these variables. Consecutive patients with recurrent endometrioid EC seen in our institution from 1989 to 2013 were retrospectively reviewed. Cox regression models were used to identify the clinicopathological factors associated with OSr. By summing scores proportionate to the hazard ratio (HR) for each significant variable, we stratified patients into 3 risk groups. Enrolled patients (n = 108) had a median time to recurrence of 15 (range, 3–163) months after initial treatment and a median OSr of 22 (range, 1–207) months. Twenty patients (18.5%) had locoregional recurrence, and 88 (81.5%) distant. One hundred three patients underwent salvage therapy; 51 (47.2%) received chemotherapy only, 22 (20.3%) received radiotherapy either alone or combined with chemotherapy, and 29 (26.9%) underwent salvage cytoreductive surgery. Multivariate regression analysis revealed that time to relapse after initial treatment, cancer antigen-125 level at recurrence, and the number of recurrent lesions were independent predictors of OSr. Incorporating these factors, we stratified patients into low-risk (n = 19), intermediate-risk (n = 43), and high-risk (n = 46) groups. The likelihood of cancer-specific death was higher in both the high-risk (HR = 8.948, 95% confidence interval [CI] = 3.498–22.893, P < .001) and the intermediate-risk (HR = 2.619, 95% CI = 1.002–6.850, P = .05) groups compared with the low-risk group. Incorporating 3 variables, recurrent endometrioid EC patients with a broad spectrum of outcome could be stratified according to OSr. This model may help predict outcomes in recurrent EC patients. |
format | Online Article Text |
id | pubmed-5457863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-54578632017-06-09 Stratification of risk groups according to survival after recurrence in endometrial cancer patients Shim, Seung-Hyuk Kim, Dae-Yeon Kim, Hyun Jung Lee, Shin-Wha Park, Jeong-Yeol Suh, Dae-Shik Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Nam, Joo-Hyun Medicine (Baltimore) 5600 To identify prognostic factors for overall survival after recurrence (OSr) in endometrioid endometrial cancer (EC) patients and categorize patient subgroups that predict outcomes using these variables. Consecutive patients with recurrent endometrioid EC seen in our institution from 1989 to 2013 were retrospectively reviewed. Cox regression models were used to identify the clinicopathological factors associated with OSr. By summing scores proportionate to the hazard ratio (HR) for each significant variable, we stratified patients into 3 risk groups. Enrolled patients (n = 108) had a median time to recurrence of 15 (range, 3–163) months after initial treatment and a median OSr of 22 (range, 1–207) months. Twenty patients (18.5%) had locoregional recurrence, and 88 (81.5%) distant. One hundred three patients underwent salvage therapy; 51 (47.2%) received chemotherapy only, 22 (20.3%) received radiotherapy either alone or combined with chemotherapy, and 29 (26.9%) underwent salvage cytoreductive surgery. Multivariate regression analysis revealed that time to relapse after initial treatment, cancer antigen-125 level at recurrence, and the number of recurrent lesions were independent predictors of OSr. Incorporating these factors, we stratified patients into low-risk (n = 19), intermediate-risk (n = 43), and high-risk (n = 46) groups. The likelihood of cancer-specific death was higher in both the high-risk (HR = 8.948, 95% confidence interval [CI] = 3.498–22.893, P < .001) and the intermediate-risk (HR = 2.619, 95% CI = 1.002–6.850, P = .05) groups compared with the low-risk group. Incorporating 3 variables, recurrent endometrioid EC patients with a broad spectrum of outcome could be stratified according to OSr. This model may help predict outcomes in recurrent EC patients. Wolters Kluwer Health 2017-05-26 /pmc/articles/PMC5457863/ /pubmed/28538383 http://dx.doi.org/10.1097/MD.0000000000006920 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 5600 Shim, Seung-Hyuk Kim, Dae-Yeon Kim, Hyun Jung Lee, Shin-Wha Park, Jeong-Yeol Suh, Dae-Shik Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Nam, Joo-Hyun Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title | Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title_full | Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title_fullStr | Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title_full_unstemmed | Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title_short | Stratification of risk groups according to survival after recurrence in endometrial cancer patients |
title_sort | stratification of risk groups according to survival after recurrence in endometrial cancer patients |
topic | 5600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457863/ https://www.ncbi.nlm.nih.gov/pubmed/28538383 http://dx.doi.org/10.1097/MD.0000000000006920 |
work_keys_str_mv | AT shimseunghyuk stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT kimdaeyeon stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT kimhyunjung stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT leeshinwha stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT parkjeongyeol stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT suhdaeshik stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT kimjonghyeok stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT kimyongman stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT kimyoungtak stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients AT namjoohyun stratificationofriskgroupsaccordingtosurvivalafterrecurrenceinendometrialcancerpatients |